Last reviewed · How we verify
Active bevacizumab and Active dexamethasone
This combination uses bevacizumab to inhibit vascular endothelial growth factor (VEGF) and reduce abnormal blood vessel formation, while dexamethasone suppresses inflammation in the eye.
This combination uses bevacizumab to inhibit vascular endothelial growth factor (VEGF) and reduce abnormal blood vessel formation, while dexamethasone suppresses inflammation in the eye. Used for Retinal diseases with abnormal neovascularization and inflammation (e.g., diabetic macular edema, retinal vein occlusion).
At a glance
| Generic name | Active bevacizumab and Active dexamethasone |
|---|---|
| Also known as | Avastin® (bevacizumab), Ozurdex® (dexamethasone intravitreal implant) |
| Sponsor | Texas Retina Associates |
| Drug class | Combination therapy: monoclonal antibody (anti-VEGF) + corticosteroid |
| Target | VEGF (bevacizumab); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
Bevacizumab is a monoclonal antibody that blocks VEGF signaling, which drives pathological neovascularization in retinal diseases. Dexamethasone is a corticosteroid that reduces inflammatory cytokines and edema. Together, they target both the angiogenic and inflammatory components of retinal pathology, particularly in conditions like diabetic macular edema or retinal vein occlusion.
Approved indications
- Retinal diseases with abnormal neovascularization and inflammation (e.g., diabetic macular edema, retinal vein occlusion)
Common side effects
- Intraocular inflammation
- Elevated intraocular pressure
- Cataract progression
- Endophthalmitis
- Systemic corticosteroid effects (with repeated dosing)
Key clinical trials
- Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: